A double blind phase 3 trial of fulvestrant with placebo or palbociclib in pre-and post-menopausal women with hormone receptor-positive (HR+ve), HER2-negative (HER2-ve) metastatic breast cancer (MBC) that progressed on prior endocrine therapy (PALOMA 3): Detailed analysis of patient-reported outcomes

Category Primary study
JournalEuropean Journal of Cancer
Year 2015
This article has no abstract
Epistemonikos ID: 3cdc705e8abce15dc5b36bbeb3dc52bf662dbd68
First added on: Feb 07, 2025